Travere Therapeutics Inc (TVTX)

Jan 6, 2025, 4:30 PM EST - 11 days ago

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:53 AM EST - 4 weeks ago

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Dec 18, 2024, 9:39 AM EST - 4 weeks ago

Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio

Nov 25, 2024, 4:30 PM EST - 7 weeks ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Nov 13, 2024, 5:00 PM EST - 2 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2024, 9:05 PM EST - 2 months ago

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 7, 2024, 4:01 PM EST - 2 months ago

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Oct 31, 2024, 3:13 PM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript

Oct 26, 2024, 7:01 AM EDT - 3 months ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Oct 21, 2024, 4:30 PM EDT - 3 months ago

Travere Therapeutics to Report Third Quarter 2024 Financial Results

Oct 17, 2024, 7:01 AM EDT - 3 months ago

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Oct 17, 2024, 2:30 AM EDT - 3 months ago

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Oct 15, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Oct 14, 2024, 4:30 PM EDT - 3 months ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Oct 14, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

Oct 13, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

Oct 11, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

Oct 10, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

Oct 9, 2024, 10:00 AM EDT - 3 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Oct 8, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Oct 7, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

Oct 2, 2024, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

Sep 30, 2024, 8:00 AM EDT - 3 months ago

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Sep 26, 2024, 4:01 PM EDT - 4 months ago

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Sep 10, 2024, 4:01 PM EDT - 4 months ago

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Sep 9, 2024, 4:50 PM EDT - 4 months ago

Overlooked Stock: TVTX

Sep 6, 2024, 9:20 AM EDT - 4 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

LGND

Sep 5, 2024, 5:34 PM EDT - 4 months ago

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Aug 30, 2024, 4:23 PM EDT - 5 months ago

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 22, 2024, 4:30 PM EDT - 5 months ago

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Aug 3, 2024, 2:38 AM EDT - 6 months ago

Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 6 months ago

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 4:30 PM EDT - 6 months ago

Travere Therapeutics to Report Second Quarter 2024 Financial Results

Jul 8, 2024, 4:30 PM EDT - 6 months ago

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

May 9, 2024, 4:30 PM EDT - 9 months ago

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

May 6, 2024, 9:33 PM EDT - 9 months ago

Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:01 PM EDT - 9 months ago

Travere Therapeutics Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:30 PM EDT - 9 months ago

Travere Therapeutics to Report First Quarter 2024 Financial Results

Apr 24, 2024, 7:05 AM EDT - 9 months ago

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy